FDA Lifts Clinical Hold on Cellectis CAR-T Trials – Genetic Engineering & Biotechnology News (blog)
Endpoints News |
FDA Lifts Clinical Hold on Cellectis CAR–T Trials
Genetic Engineering & Biotechnology News (blog) Cellectis said the FDA has lifted the clinical hold placed in September on the company's two Phase I studies of its universal gene-edited allogeneic chimeric antigen receptor T–cell (CAR-T) immunotherapy candidate UCART123 following the death of a … FDA lifts clinical hold on Cellectis CAR–T FDA gives Cellectis a green light to relaunch off-the-shelf CAR–T studies — with several strings attached FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN |
